AtriCure, Inc. specializes in the development and manufacturing of innovative surgical devices primarily focused on cardiac arrhythmias and pain management. The company's product portfolio is anchored by the Isolator Synergy Ablation System, which was the first medical device to receive FDA approval for treating persistent atrial fibrillation (Afib). Additionally, AtriCure produces the AtriClip Left Atrial Appendage Exclusion System, a widely used LAA management device, and the cryoSPHERE probes for temporary nerve ablation to manage post-operative pain in cardiac and thoracic procedures. While the majority of its revenue is generated in the United States, the company maintains a growing international footprint across Europe and Asia. AtriCure primarily serves electrophysiologists, cardiothoracic surgeons, and thoracic surgeons in hospital settings worldwide.
